Industry Data & Market Research

2021 U.S. Industry Statistics & Market Research - Research & Development in the Physical, Engineering & Life Sciences

Market Size & Industry Statistics

The total U.S. industry market size for Research & Development in the Physical, Engineering & Life Sciences: Industry statistics cover all companies in the United States, both public and private, ranging in size from small businesses to market leaders. In addition to revenue, the industry market analysis shows information on employees, companies, and average firm size.

Investors, banks, and business executives use growth rates and industry trends to understand the market outlook and opportunity.

Research & Development in the Physical, Engineering & Life Sciences market size 2021
Charts and graphs can be copied to Microsoft Word and Powerpoint presentations.

Statistics 2014        2015        2016        2017        2018        2019        2020
Market Size
(Total Sales/Revenue)

Order at top of page
Total Firms
Total Employees
Average Revenue Per Firm
Average Employees Per Firm
Average Revenue Per Employee
Statistics Source: U.S. Census, AnythingResearch Analysis of Federal Data

Market Forecast

Market forecasts show the long term industry outlook and future growth trends. The following extended five-year / six-year demand forecast projects both short-term and long-term trends.

Forecast / Industry Outlook 2021 2022 2023 2024 2025
Market Forecast ($ millions)
Projected Industry Growth Rate (%)
Source: AnythingResearch Economic Analysis

Product & Services Breakdown

Research products and services in the Research & Development in the Physical, Engineering & Life Sciences industry generating sales. Note that products are broken into categories with different levels of classification.

Product DescriptionNumber of Companies Sales ($ millions) Percent of Total Sales

Industry Total

Basic And Applied Research In The Physical And Engineering Sciences

Basic And Applied Research In - Chemistry And Chemical Engineering

Basic And Applied Research In - Computer, Electrical, And Electronic Engineering

Basic And Applied Research In - Earth And Environmental Sciences

Basic And Applied Research In - Material, Mechanical, And Industrial Engineering

Basic And Applied Research In - Physics

Basic And Applied Research In - Astronomy

Basic And Applied Research In - Other Physical Sciences, Including Math, And Other Natural And Exact Sciences (Exclude Biologica

Basic And Applied Research In - Other Engineering Sciences, Including Civil, Construction, And Other Engineering

Computer Systems Design, Development, And Integration Services

Testing Services (Physical Or Product), Excluding Medical And Veterinary Services

Basic And Applied Research In Biotechnology

Basic And Applied Research In The Life Sciences (Exclude Biotechnology.)

Basic And Applied Research In - Pharmacology And Pharmaceutical Sciences

Basic And Applied Research In - Medical And Health Sciences

Basic And Applied Research In - Biological Science

Basic And Applied Research In - Agriculture, Forestry, And Allied Sciences

Basic And Applied Research In - Animal Production, Fisheries, And Veterinary Sciences

Basic And Applied Research In - Other Life Sciences, Excluding Biotechnology

Basic And Applied Research In The Social Sciences And Humanities

Basic And Applied Research In - Education

Development Services For Goods

Development Services For Service Products Processes, Systems, Or Methods

Outright Sale Of Original Works Of Intellectual Property

Advisory And Consulting Services For Research And Development Activities

Engineering Services

Licensing Of Rights To Use Intellectual Property

Licensing Of Rights To Use Intellectual Property Protected By Copyright

Licensing Of Rights To Use Intellectual Property Protected As Industrial Property

Resale Of Merchandise

All Other Receipts

All Other Operating Receipts

Contributions, Gifts, And Grants - Government

Contributions, Gifts, And Grants - Private

Investment Income, Including Interest And Dividends

All Other Revenue

U.S. Geographic Distribution: Revenue Statistics by State

Market Size by State ($ millions) indicates how the industry's competition is distributed throughout the country. State-level information can identify areas with higher and lower industry market share than average.

U.S. map by state

Income Statement (Average Financial Metrics)

Financial metrics provide a snapshot view of a benchmark "average" company. Key business metrics show revenue and operating costs. The data collected covers both public and private companies.

Industry AveragePercent of Sales
(Industry Benchmark)
Total Revenue

Order at top of page
Operating Revenue
Cost of Goods Sold
Gross Profit

Operating Expenses
Pension, profit sharing plans, stock, annuity
Rent paid on business property
Charitable Contributions
Domestic production activities deduction
Compensation of officers
Salaries and wages
Employee benefit programs
Taxes and Licenses
Bad Debts
Other Operating Expenses
Total Operating Expenses
Operating Income
Non-Operating Income
EBIT (Earnings Before Interest and Taxes)
Interest Expense
Earnings Before Taxes
Income Tax
Net Profit
Net Income
Source: AnythingResearch Analysis of U.S. federal statistics

Financial Ratio Analysis

Financial ratio information can be used to benchmark how a Research & Development in the Physical, Engineering & Life Sciences company compares to its peers. Accounting statistics are calculated from the industry-average for income statements and balance sheets.

Profitability & Valuation RatiosIndustry Average
Company valuation can be measured based on the firm's own performance, as well as in comparison against its industry competitors. These metrics show how the average company in the Research & Development in the Physical, Engineering & Life Sciences industry is performing.
Profit Margin
Gross Profit Margin, Operating Profit Margin, and Net Profit Margin. Show company earnings relative to revenues.
Return on Equity (ROE)
Return on Equity (ROE) is net income as a percentage of shareholders' equity. Shareholders' Equity is defined as the company's total assets minus total liabilities. ROE shows how much profits a company generates with the money shareholders invested (or with retained earnings).
Return on Assets (ROA)
Return on Assets (ROA) is net income relative to total assets. The market research on Research & Development in the Physical, Engineering & Life Sciences measures how efficiently the company leverages its assets to generate profit. ROA is calculated as Net Income divided by Total Assets.

Liquidity RatiosIndustry Average
Bankers and suppliers use liquidity to determine creditworthiness and identify potential threats to a company's financial viability.
Current Ratio
Measures a firm's ability to pay its debts over the next 12 months.
Quick Ratio (Acid Test)
Calculates liquid assets relative to liabilities, excluding inventories.

Efficiency Ratios - Key Performance IndicatorsIndustry Average
Measure how quickly products and services sell, and effectively collections policies are implemented.
Receivables Turnover Ratio
If this number is low in your business when compared to the industry average in the research report, it may mean your payment terms are too lenient or that you are not doing a good enough job on collections.
Average Collection Period
Based on the Receivables Turnover, this estimates the collection period in days. Calculated as 365 divided by the Receivables Turnover
Inventory Turnover
A low turnover rate may point to overstocking, obsolescence, or deficiencies in the product line or marketing effort.
Fixed-Asset Turnover
Generally, higher is better, since it indicates the business has less money tied up in fixed assets for each dollar of sales revenue.

Compensation & Salary Surveys for Employees

Compensation statistics provides an accurate assessment of industry-specific jobs and national salary averages. This information can be used to identify which positions are most common, and high, low, and average annual wages.

TitlePercent of WorkforceBottom Quartile Average (Median) SalaryUpper Quartile
Management Occupations 14%

Order at top of page
Chief Executives0%
General and Operations Managers2%
Other Management Occupations 6%
Business and Financial Operations Occupations 10%
Business Operations Specialists 8%
Computer and Mathematical Occupations 12%
Computer Occupations 11%
Software Developers and Programmers 5%
Architecture and Engineering Occupations 17%
Engineers 14%
Life, Physical, and Social Science Occupations 25%
Life Scientists 12%
Medical Scientists 7%
Medical Scientists, Except Epidemiologists 7%
Life, Physical, and Social Science Technicians 7%
Office and Administrative Support Occupations 9%
Source: Bureau of Labor Statistics

Research & Development in the Physical, Engineering & Life Sciences Competitor Landscape & Key Companies [PREMIUM]

The most influential companies in the Research & Development in the Physical, Engineering & Life Sciences industry and adjacent industries either have large market share or are developing new business models and methods that could disrupt the status quo. We look at leading and emerging companies in the Research & Development in the Physical, Engineering & Life Sciences industry and adjacent sectors:

Market Leaders:
Direct Competitors

Companies with the largest market share, focused in this industry
Market leaders:
Diversified Competitors

Largest companies that have diversified operations in this and other industries
Direct Competitors

Innovative, Emerging, and Disruptive Companies that may influence the future direction of the industry.
Diversified Competitors

Innovators and Disruptors in adjacent industries that may also affect the Research & Development in the Physical, Engineering & Life Sciences industry.

Executive Briefings

We are engaged in segments of the pharmaceutical industry that are highly competitive and rapidly changing. Many large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are commercializing or pursuing the development of products that target HCV, RSV, HBV, NASH, hMPV and SARS-CoV-2 and other viral infections or liver diseases that we may target in the future. Many of our competitors have substantially greater commercial infrastructures and financial, technical and personnel resources than we have, as well as drug candidates in late-stage clinical development. We will not be able to compete successfully unless we are able to:   • design and develop products that are superior to other products in the market;   • attract qualified scientific, medical, regulatory, sales and marketing and commercial personnel;   • obtain patent and/or other proprietary protection for our processes and product candidates;   • obtain required regulatory approvals; or   • collaborate with others in the development and commercialization of new products. Established competitors may invest heavily to quickly discover and develop novel compounds that could make our product candidates obsolete. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety, or some combination of these factors, to overcome competition and to be commercially successful. We expect AbbVie’s MAVYRET/MAVIRET to continue to face intense competition due to existing approved products in the HCV market. AbbVie’s HCV treatment regimens currently face competition in various world markets and subpopulations of HCV from Gilead’s Epclusa® (a fixed dose combination of sofosbuvir and velpatasvir), Vosevi® (a triple combination therapy of sofosbuvir, velpatasvir and voxilaprevir approved by the FDA in July 2017 for specified sofosbuvir -treatment failures and NS5A-inhibitor treatment failures) and Harvoni® (a fixed-dose combination of sofosbuvir and ledipasvir); and to a lesser extent - Merck’s Zepatier® (a fixed-dose combination of grazoprevir and elbasvir). Gilead launched authorized generic versions of Epclusa and Harvoni in January 2019 through a newly created subsidiary, Asegua Therapeutics, LLC, which has had an impact on the competitive landscape. Other competitive products in the form of other treatment methods or a vaccine for HCV may render AbbVie’s HCV regimens obsolete or noncompetitive. AbbVie’s regimens that contain one of our collaboration’s protease inhibitors will face competition based on their safety and effectiveness, reimbursement coverage, price, patent position, AbbVie’s marketing and sales capabilities, and other factors. If any of AbbVie’s HCV regimens face competition from generic products other than authorized generic versions by the manufacturer of the branded product (i.e. If AbbVie is not able to compete effectively against its competitors in HCV, our business will not grow and our financial condition, operations and stock price will suffer. 16   We also expect our other product candidates to face intense and increasing competition in the NASH and antiviral markets as advanced technologies and products become available. Though there is currently no approved treatment for NASH, we expect significant competition from other companies in the development of new treatments for NASH and related conditions. In February 2019, Intercept Pharmaceuticals announced positive Phase 3 trial results for OCA (brand name Ocaliva®) in NASH and submitted U.S. We are aware of several other companies with NASH programs that are significantly more advanced than ours, including companies with compounds in Phase 3 clinical trials in NASH, namely AbbVie, Galmed, Intercept, and Madrigal. In addition, a number of companies have NASH or related programs with compounds in Phase 2 clinical trials. These companies include 89bio, Afimmune, Akcea, Akero, AngioLab, AstraZeneca, BMS, Can-Fite BioPharma, Cirius, Cymabay, Eli Lilly and Company, Enyo, Galectin, Gilead, HighTide Biopharma, Immuron, Inventiva, Kowa Company, Lipocine, Medicinova, Metacrine, Mitsubishi Tanabe Pharma, NGM Biopharmaceuticals, Northsea Therapeutics, Novartis, Novo Nordisk, NuSirt Biopharma, Pfizer, Poxel SA, PharmaKing, Sagimet Biosciences, TaiwanJ Pharmaceuticals, Terns, Theratechnologies, Viking Therapeutics, and Zydus. A significant number of other companies are conducting earlier stage clinical trials that may be applicable in NASH. There are also additional companies conducting preclinical studies in these disease areas. Similarly, HBV and RSV represent competitive therapeutic areas. Many companies are seeking to develop new HBV drugs that alone or in combination with other mechanisms could lead to a functional cure of HBV. Assembly, Gilead, GSK/Ionis, HEC, Johnson Enanta Pharmaceuticals

Government Contracts

In 2020, the federal government spent a total of $331,844,138,177 on Research & Development in the Physical, Engineering & Life Sciences. It has awarded 12589 contracts to 3386 companies, with an average value of $98,004,766 per company.   

Most Recent Contracts Date Total Award Amount

Related Reports

Can't find what you're looking for? We have over a thousand market research reports. Ask us and an analyst will help you find what you need.

Industries Related to Research & Development in the Physical, Engineering & Life Sciences

Research & Development in the Physical, Engineering & Life Sciences